Compare AVLN & OBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVLN | OBK |
|---|---|---|
| Founded | N/A | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2026 | 2018 |
| Metric | AVLN | OBK |
|---|---|---|
| Price | $29.23 | $51.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.67 |
| AVG Volume (30 Days) | ★ 545.5K | 138.0K |
| Earning Date | N/A | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.89 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.43 |
| Revenue Next Year | N/A | $5.79 |
| P/E Ratio | ★ N/A | $56.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.33 | $32.13 |
| 52 Week High | $33.32 | $52.90 |
| Indicator | AVLN | OBK |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 58.69 |
| Support Level | $27.37 | $48.10 |
| Resistance Level | $33.32 | N/A |
| Average True Range (ATR) | 2.54 | 1.11 |
| MACD | -0.26 | -0.12 |
| Stochastic Oscillator | 31.72 | 56.57 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.